← Human Trials & Peer-Reviewed Studies
Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis
Plain-language guide to PMID 25393645 (2015): double-blind randomized controlled trial study of Abaloparatide and Teriparatide, osteoporosis and bone density.
Key Facts
- PMID
- 25393645
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2015
- Study type
- Randomized Controlled Trial
- Authors
- Leder BZ et al. (8 authors)
- DOI
- 10.1210/jc.2014-3718
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Abaloparatide and Teriparatide in the context of osteoporosis and bone density, published as a randomized controlled trial.
This study sought to assess the effects of abaloparatide on bone mineral density (BMD) at the lumbar spine, total hip, and femoral neck in postmenopausal women with osteoporosis.
Why It Was Studied
Abaloparatide is a novel synthetic peptide analog of parathyroid hormone-related protein (PTHrP) that is currently being developed as a potential anabolic agent in the treatment of postmenopausal osteoporosis.
Who Took Part
PubMed indexes the participants as middle-aged adults, older adults and people over 80, women only.
A 24-week extension was also performed in a subset of subjects.
Postmenopausal women with osteoporosis (n = 222).
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
The participants were allocated by chance, so the Abaloparatide group and the comparison group should start out alike.
Neither the participants nor the staff measuring them knew who was on Abaloparatide, so expectations could not easily colour the readings.
A placebo (an inactive look-alike) gave the Abaloparatide group a baseline to be compared against.
What Was Measured
The subject headings attached to it are Bone Density, Bone Density Conservation Agents, Femur Neck, Lumbar Vertebrae, Osteoporosis, Postmenopausal, Parathyroid Hormone-Related Protein and Radiography.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Abaloparatide and Teriparatide in people with osteoporosis and bone density.
Results are reported in around 10 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2015 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Abaloparatide compound page and the Teriparatide compound page, Osteoporosis and bone density research.
Our Notes on the Compounds
Abaloparatide: A synthetic parathyroid hormone-related peptide (PTHrP) analog used as a bone-building (anabolic) osteoporosis medicine.
Teriparatide: A parathyroid hormone fragment, PTH(1-34), with human trials and approved-pen labeling; the research vial is not the approved pen.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.